The APTT Response of Pregnant Plasma to Unfractionated Heparin^[1]

Summary

Pregnancy is associated with a physiological increase in coagulation factors and heparin binding proteins; both can affect the activated partial thromboplastin time (APTT) in response to unfractionated heparin (UFH) invalidating the use of a non-pregnant APTT therapeutic range. We compared the anticoagulant response of UFH added in vitro to the plasma of 13 pregnant (third trimester) and 15 nonpregnant women to determine whether the measured APTT and antifactor Xa activities are lower in pregnancy. Increasing concentrations of UFH were added to platelet-poor plasma from each subject and the APTT and anti-factor Xa activity were measured. The amount of UFH which was reversibly bound and neutralised by plasma heparin binding proteins was assessed by comparing the anti-factor Xa activity before and after addition of low affinity heparin (LAH). Fibrinogen, von Willebrand factor antigen (vWF Ag) and factor VIII levels, were also measured. The APTT response, assessed by the slope of the regression line of log APTT versus added heparin concentration, was attenuated in pregnant plasma (0.76 s/U/mL versus 1.2 s/U/mL, p = 0.005) and was highly correlated to increased non-specific plasma protein binding (47% versus 35% p <0.01) and increased fibrinogen (5.1g/L versus 2.8 g/L, p <0.01) and factor VIII activity (2.7 U/mL versus 1.2 U/mL, p <0.01). Thus, to achieve the same heparin level, pregnant women require higher daily doses of UFH than non-pregnant women. However, if UFH dose adjustments during the third trimester are based upon a non-pregnant APTT therapeutic range, systematic overdosing of pregnant women will result, possibly increasing the risk of bleeding and osteoporosis.

Keywords

Unfractionated heparin - pregnancy - activated partial thromboplastin time (APTT) - anti-factor Xa activity

• References

• 1 Ginsberg JS, Hirsh J, Turner C, Levine MN, Burrows R. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost 1989; 61: 197-203.
• 2 Ginsberg JS, Kowalchuck G, Hirsh J, Brill-Edwards P. Heparin therapy during pregnancy: risks to the fetus and mother. Arch Int Med 1989; 149: 2233-36.
• 3 Chui HM, Hirsh J, Yung WL, Regoeczi E, Gent M. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood 1977; 49: 171-84.
• 4 Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH, Rosenbloom D, Sackett DL, Anderson C, Harrison L. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis. N Engl J Med 1986; 315: 1109-14.
• 5 Levine MN, Hirsh J, Gent M, Turpie AGG, Cruickshank M, Weitz J, Anderson D, Johnson M. A randomised trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Int Med 1994; 154: 49-56.
• 6 Brill PEdwards, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Int Med 1993; 119: 104-9.
• 7 Van den Besselaar AHMP, Meeuwise-Braun J, Bertina RM. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples. Thromb Haemost 1990; 63: 16-23.
• 8 Hirsh J. Drug therapy: Heparin. N Engl J Med 1991; 324: 1565-74.
• 9 Barzu T, van Rijn JLML, Petitou M, Tobelem G, Caen JP. Heparin degradation in endothelial cells. Thromb Res 1987; 47: 601-9.
• 10 Young E, Cosmi B, Weitz J, Hirsh J. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (enoxaparin) to plasma proteins. Thromb Haemost 1993; 70: 625-30.
• 11 Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992; 67: 639-43.
• 12 Sterling E, Woolf L, North WRS, Seghatchian TWMeade. Haemostasis in normal pregnancy. Thromb Haemost 1984; 52: 176-82.
• 13 Rucinski B, Niewiarowski S, Strzyzewski M, Holt JC, Mayo KH. Human platelet factor 4 and its C-terminal peptide: heparin binding and clearance from the circulation. Thromb Haemost 1990; 63: 493-8.
• 14 Wu Hai-Feng, Lundblad RL, Church FC. Neutralisation of heparin activity by neutrophil lactoferrin. Blood 1995; 85: 421-8.
• 15 Rebelo I, Carvalho-Guerra F, Pereira-Leite L, Quintanilha A. Lactoferrin as a sensitive marker of neutrophil activation in normal pregnancies. Eur J Obstet Gynecol Reprod Biol 1995; 62: 189-94.
• 16 Baruch D, Ajzenberg N, Denis C, Legendre P, Lormeau JC, Meyer D. Binding of heparin fractions to von Willebrand factor: effect of molecular weight and affinity for antithrombin III. Thromb Haemost 1994; 71: 141-6.
• 17 Ayhan A, Akkok E, Urman B, Yarali H, Dundar S, Kirazli S. Beta thromboglobulin and platelet factor 4 levels in pregnancy and pre-eclampsia. Gynecol Obstet Invest 1990; 30: 12-4.
• 18 Robinson GE, Burren T, Mackie IJ, Bounds W, Walshe K, Faint R, Guillebaud J, Machin SJ. Changes in haemostasis after stopping the oral combined contraceptive pill: implications for major surgery. BMJ 1991; 302: 269-71.
• 19 Notelovitz M, Kitchens CS, Khan FY. Changes in coagulation and anticoagulation in women taking low dose triphasic oral contraceptive: A controlled comparative 12 month clinical trial. Am J Obstet Gynecol 1992; 167: 1255-61.
• 20 Young E, Hirsh J. Contribution of red blood cells to the saturable mechanism of heparin clearance. Thromb Haemost 1990; 64: 559-63.
• 21 Casu B, Diamantini G, Fedeli G. et al. Retention of antilipemic activity by periodated-oxidised non anticoagulant heparins. Arzneim Forsch/Drug Res 1986; 36: 637-42.
• 22 Biggs R, Rizza CR. Human blood coagulation, haemostasis and thrombosis. 3rd ed. London: Blackwell Scientific Publications; 1984
• 23 Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematologica 1957; 17: 237-9.
• 24 Whitefield LR, Lele A, Levy G. Effect of pregnancy on the relationship between concentration and the anticoagulant action of heparin. Clin Pharmacol Ther 1983; 34: 23-8.
• 25 Brancazio LR, Roperti KA, Stierer R, Laifer SA. Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. Am J Obstet Gynecol 1995; 1240-5.
• 26 Whitaker PG, Macphail S, Lind T. Serial hematological changes and pregnancy outcome. Obstet Gynecol 1996; 88: 33-9.
• 27 Bain B, Forester T, Sleigh B. Heparin and the activated partial thromboplastin time – A difference between the in vitro and in vivo effects and implications for the therapeutic range. AJCP 1980; 74: 668-73.
• 28 Manson L, Weitz J, Podor TJ, Hirsh J, Young E. The variable anticoagulant response to unfractionated heparin in vivo reflects binding to plasma proteins rather than clearance. J Lab Clin Med 1997; 130: 649-55.
• 29 Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AGG, Demers C, Kovacs M. A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-81.
• 30 Sanson BJ, Lensing AWA, Prins MH. et al. Safety of low molecular weight heparin in pregnancy: A systematic review. Thromb Haemost 1999; 81: 668-72.
• 31 Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumadin. Thromb Haemost 1994; 71: 7-11.
• 32 Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5.
• 33 Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF, Kher A, Aiach M, Fiessinger JN. Adjusted versus fixed doses of low molecular weight heparin (Fragmin) in the treatment of deep vein thrombosis. Thromb Haemost 1994; 71: 698-702.